Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.
Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $4.2 billion in milestone payments.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Novartis is paying Voyager Therapeutics $54 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene therapies. Depending on the progress of the research, Voyager could earn up to $1.5 billion in milestone payments.
The gene therapy pipeline of Voyager Therapeutics has hit several setbacks in the past year, but a strategy shift to its capsid technology is now showing promise. Pfizer has signed on as partner in a wager that Voyager’s tech holds the key to delivery of gene therapies for cardiovascular and neurological disorders.
The Neurocrine decision follows a clinical hold placed on the Parkinson’s program in December. It’s Voyager’s second loss of an R&D partner in the past year; AbbVie previously ended an alliance aiming to develop gene therapies for Parkinson’s and Alzheimer’s.
Voyager will gain worldwide rights to its Huntington's disease therapy candidate, transfer rights to another product candidate to Neurocrine and pay Sanofi $20 million.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The biotech IPO parade marches on with two IPOs: Wave Life Sciences priced out at $102 million today, and Voyager Life Sciences raised $70 million.
Cambridge gene therapy startup Voyager Therapeutics just wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinson’s disease. Voyager is using the money to advance its five clinical and preclinical programs, as well as a platform developed around adeno-associated viruses. New investors include Brookside Capital […]